Patents by Inventor Yuqiang Wang

Yuqiang Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5843937
    Abstract: The present invention relates to novel DNA alkylating agents and the prodrugs of these agents which are useful as antitumor agents and DNA labelling agents. The compounds are hydroxy dihydrobenzindole oligopeptides and prodrugs thereof wherein the monomeric constituents are derived from monocyclic or bicyclic heterocyclic aromatic residues.
    Type: Grant
    Filed: May 23, 1996
    Date of Patent: December 1, 1998
    Assignee: Panorama Research, Inc.
    Inventors: Yuqiang Wang, Susan C. Wright, James W. Larrick
  • Patent number: 5502068
    Abstract: The invention is directed to novel cyclopropylpyrroloindole-oligopeptide compounds which are useful as anticancer agents. The novel cyclopropylpyrroloindole-oligopeptide compounds have the following general structure: ##STR1## wherein, Het.sup.1 and Het.sup.2 are individually selected from the group consisting of pyrrole, imidazole, triazole, thiophene, furan, thiazole, oxazole and pyrazole,R is selected from the group consisting of a valence bond; a C.sub.1 -C.sub.6 alkyl; a C.sub.2 -C.sub.6 alkenyl; a C.sub.2 -C.sub.6 alkynyl; and an ortho, meta or para linked aromatic group,A is selected from the group consisting of a C.sub.1 -C.sub.6 alkyl group; an amidine or derivative thereof; a guanidine; a secondary, tertiary or quaternary ammonium salt; and a sulfonium salt,n is 0 to 3, andm is 0 to 3.
    Type: Grant
    Filed: January 31, 1995
    Date of Patent: March 26, 1996
    Assignee: Synphar Laboratories, Inc.
    Inventors: J. William Lown, Yuqiang Wang, Weide Luo
  • Patent number: 4841085
    Abstract: A compound having the structure ##STR1## wherein R is CH.sub.3 or C.sub.2 H.sub.5 1; R.sup.1 is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.2 H.sub.4 Cl, N(CH.sub.3).sub.2, N(C.sub.2 H.sub.5).sub.2, N(C.sub.2 H.sub.4 Cl).sub.2, OCH.sub.3, C.sub.2 H.sub.5, CH.sub.3, or C.sub.2 H.sub.5, and R.sup.2 is N(C.sub.2 H.sub.4 Cl).sub.2 or NH C.sub.2 H.sub.4 Cl.These compounds may be used to eliminate occult leukemic clonogenic cells from bone marrow by contacting the bone marrow with a solution comprising levels of said compound sufficient to eliminate occult leukemic clonogenic cells. Analogously tumor cells in a host or organ of a host may be eliminated by treatment of the host or host's organ with a compound of this description.Compounds of this description are stable aldophosphamide analogs activatable by the action of an esterase and a subsequent E-2 elimination reaction to form acrolein and a phosphoramidic mustard of the formula: ##STR2## wherein R is NH.sub.2, NHCH.sub.3, NHC.sub.2 H.sub.5, NHC.sub.2 H.
    Type: Grant
    Filed: June 30, 1986
    Date of Patent: June 20, 1989
    Assignee: Board of Regents, University of Texas System
    Inventors: David Farquhar, Yuqiang Wang